Phillips-Medisize and Exact Sciences (NSDQ:EXAS) today announced a collaboration to advance early cancer detection.
The collaboration centers around Exact Sciences’ Cologuard, the first and only FDA-approved, non-invasive stool DNA screening test for colorectal cancer, according to a news release.
Phillips-Medisize, a Molex company, said the collaboration will seek to focus on the patient experience through the simplicity and convenience of at-home testing. The company developed new tooling to safeguard against inadvertent leaks while meeting specifications and tolerances required to produce the highest levels of product quality.
Exact Sciences was able to utilize supply chain flexibility to acquire all components needed to rapidly scale production of the kit, while Phillips-Medisize located and validated alternate supply sources, conducted risk assessments and forecasting and created sourcing and procurement plans to protect against unplanned disr…